CDCA7L antibody (C-Term)
Quick Overview for CDCA7L antibody (C-Term) (ABIN1881189)
Target
See all CDCA7L AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- AA 290-317, C-Term
-
Purification
- This antibody is purified through a protein A column, followed by peptide affinity purification.
-
Immunogen
- This CDCA7L antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 290-317 amino acids from the C-terminal region of human CDCA7L.
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
- WB: 1:1000
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Expiry Date
- 6 months
-
-
-
: "Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells." in: Cancer research, Vol. 65, Issue 13, pp. 5607-19, (2005) (PubMed).
: "R1, a novel repressor of the human monoamine oxidase A." in: The Journal of biological chemistry, Vol. 280, Issue 12, pp. 11552-9, (2005) (PubMed).
: "Human chromosome 7: DNA sequence and biology. ..." in: Science (New York, N.Y.), Vol. 300, Issue 5620, pp. 767-72, (2003) (PubMed).
-
-
- CDCA7L (Cell Division Cycle Associated 7-Like (CDCA7L))
-
Alternative Name
- CDCA7L
-
Background
- Plays a role in transcriptional regulation as a repressor that inhibits monoamine oxidase A (MAOA) activity and gene expression by binding to the promoter. Plays an important oncogenic role in mediating the full transforming effect of MYC in medulloblastoma cells. Involved in apoptotic signaling pathways, May act downstream of P38-kinase and BCL-2, but upstream of CASP3/caspase-3 as well as CCND1/cyclin D1 and E2F1.
-
UniProt
- B3KTR5
Target
-